Nonapeptide-1 Peptide – The MC1R Antagonist for Pigmentation Research
Nonapeptide-1, also known as Melanostatine-5, is a synthetic peptide identified through extensive library screening as one of the most effective inhibitors of the Melanocortin-1 Receptor (MC1R). Unlike agonists that stimulate tanning, Nonapeptide-1 acts as a biological “brake,” preventing the signaling cascade that leads to melanin overproduction.
Key Research Areas:
- Melanin Synthesis Inhibition: Research suggests that Nonapeptide-1 interferes with the binding of alpha-melanocyte-stimulating hormone (α-MSH) to its receptor. This blockade prevents the activation of tyrosinase, the rate-limiting enzyme in melanin production, effectively reducing pigment synthesis in experimental models.
- MC1R Downregulation: In vitro studies on human epidermal melanocytes (HEM) indicate that Nonapeptide-1 may decrease the actual expression levels of the MC1R receptor. This downregulation makes cells less responsive to pigment-stimulating signals, even under UV exposure.
- Transcriptional Regulation (MITF): Nonapeptide-1 appears to lower the expression of the microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte development. By modulating MITF, the peptide reduces the levels of key proteins such as TRP1 and TRP2.
- Hyperpigmentation & Melasma: Due to its ability to prevent the “tanning” signal at the source, this peptide is at the forefront of research involving hyperpigmentation disorders, including melasma and age spots.
- Phototoxicity Research: While it does not provide a physical barrier like SPF, Nonapeptide-1 is used to study how the skin’s biological response to UVA radiation can be modulated to prevent unwanted post-inflammatory hyperpigmentation.
Elite Peptide Supply provides high-purity Nonapeptide-1 for laboratory investigation. Our peptide is synthesized with precision, ensuring the D-Trp and D-Phe residues are correctly positioned to maintain maximum antagonistic potential at the MC1R site.
Reviews
There are no reviews yet.